Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.
Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.
The strong finish to 2023 didn’t last into 2024 as Biotech and Life Science stocks moved sideways the last month and were unable to keep pace with the general stock market, which managed to climb to new record highs.
Very confident CEO Magnus Corfitzen re-iterated quality in Phase-3 data on Orviglance and Phase-1 data in Oncoral. Ascelia Pharma has recently secured capital until Q2-2025.
The topic for this event is the Q4 and Full-Year report and major events during the last quarter in 2023. In Q4, Ascelia Pharma announced a re-start of the Imaging Reading Phase and re-confirmed Phase 3 SPARKLE results by May 2024. Ascelia Pharma will update the investor community on the roll-out strategy for Orviglance to the market.
Ascelia Pharma’s stock price has soared in 2024 with the stock up almost 160 percent since New Year. Adding the return from the latter part of December 2023, the stock is up more than 200 percent since the company in the beginning of December announced that the re-evaluation of the Orviglance data is on track.
Meet and ask questions CEO Magnus Corfitzen from Ascelia Pharma on 9 November at 2.30PM CET.
The topic for this event is the Q3 report and major events during the quarter. It’s been a very busy quarter for Ascelia Pharma with major news flow on the Sparkle study.